- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 15.05. | Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M | 2 | Seeking Alpha | ||
| 15.05. | Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025 | 2 | Seeking Alpha | ||
| 14.05. | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 71 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
| 07.05. | Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 | 2 | GlobeNewswire (USA) | ||
| 30.04. | Why Journey Medical Corporation (DERM) is Surging in 2025 | 1 | Insider Monkey | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 03.04. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | Journey Medical appoints Ramsey Alloush as COO | 1 | Seeking Alpha | ||
| 01.04. | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 86 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 01.04. | Journey Medical appoints new COO amid growth phase | 2 | Investing.com | ||
| 26.03. | Journey Medical GAAP EPS of -$0.72 beats by $0.44, revenue of $56.13M misses by $0.59M | 4 | Seeking Alpha | ||
| 26.03. | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 632 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen | |
| 24.03. | Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea | 3 | GlobeNewswire (USA) | ||
| 24.03. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 | 3 | GlobeNewswire (USA) | ||
| 05.03. | FDA approves new rosacea treatment from Journey Medical | 2 | Investing.com | ||
| 04.03. | Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida | 1 | GlobeNewswire (USA) | ||
| 20.02. | Journey Medical Corporation (DERM): A Bull Case Theory | 1 | Insider Monkey | ||
| 05.02. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 24.01. | Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) | 2 | Insider Monkey |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,640 | +2,13 % | Goldgrube US-Gesundheitswandel: Wie sind Bayer, PanGenomic Health und Pfizer aufgestellt? | Das US-Gesundheitswesen erlebt unter Minister Robert F. Kennedy Jr. einen beispiellosen Umbruch. Pharmariesen ächzen unter drastischen Preiskontrollen und regulatorischen Erdbeben, während digitale... ► Artikel lesen | |
| GILEAD SCIENCES | 97,00 | +0,43 % | Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions" | NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 393,00 | +1,28 % | Vertex Pharmaceuticals-Aktie an der Börse auf der Verliererseite: Börsenkurs fällt deutlich (381,9154 €) | Im US-amerikanischen Wertpapierhandel fällt derzeit die Aktie von Vertex Pharmaceuticals negativ auf. Das Wertpapier verbilligt sich am Mittwoch deutlich. Ein Kurssturz auf zwischenzeitlich 433,39 US-Dollar... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,164 | -0,75 % | EyePoint advances with Duravyu Phase III trial | ||
| ASTRIA THERAPEUTICS | 4,680 | +2,18 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four... ► Artikel lesen | |
| ROCKET LAB | 24,250 | +4,89 % | Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30? | ||
| OPKO HEALTH | 1,160 | -3,53 % | Opko Health auf Jefferies-Konferenz: Strategische Umstrukturierung und Wachstumspläne | ||
| LIGAND PHARMACEUTICALS | 88,50 | -2,75 % | ROUNDUP: Ligand Pharmaceuticals Reiterates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 95,92 | +0,84 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ... | Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up... ► Artikel lesen | |
| ROYALTY PHARMA | 29,010 | -1,69 % | Dividendenbekanntmachungen (16.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADIDAS AG DE000A1EWWW0 - 2 EUR AF GRUPPEN ASA NO0003078107 5 NOK 0,4289 EUR AIXTRON SE DE000A0WMPJ6 - 0,15 EUR ALGOMA CENTRAL CORPORATION CA0156441077 0... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 22,420 | +1,13 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP... ► Artikel lesen | |
| TG THERAPEUTICS | 35,360 | +2,93 % | TG Therapeutics shares MS drug trial updates | ||
| CATALENT | 59,93 | 0,00 % | Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors | Expert appointment further accelerates Prolific's ability to deliver impactful protein production solutions as it prepares to expand its light-controlled bioproduction offerings
Prolific Machines... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,850 | +1,95 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
| TALPHERA | 0,407 | -4,13 % | Talphera erhält Verlängerung zur Erfüllung der Nasdaq-Notierungsanforderungen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 7,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.